KA/EN
Register
Medicines reference
Search
Search
Active substance

Lactulose

Favourites

Osmotic laxative (disaccharide). Registered in Georgia: 1 human medicine. Forms: solution.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Lactulose
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
400 mg/kg Dog, Cat Constipation By mouth total daily dose divided into 2–3 doses
VMD SPC 2023
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Laxatract 667 mg/ml Syrup for Dogs and Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2023
4000 mg/kg
off-label
 Dog, Cat Hepatic Encephalopathy Into the rectum until a neurological response is achieved
MSD Vet Manual 2024
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Hepatic Encephalopathy in Small Animals
MSD/Merck Veterinary Manual, 2024
Before use

Safety information

Known Contraindications

  • Critical
    Do not use in animals with total gastro-intestinal obstruction, digestive perforation or risk of digestive perforation.
    Sources: VMD SPC · VMD
  • Critical
    Known hypersensitivity to lactulose or the excipient benzyl alcohol (E1519) is a contraindication.
    Sources: VMD SPC · VMD
  • Warning
    Lactulose solution contains free lactose and galactose and may alter insulin requirements in patients with diabetes mellitus. Monitor blood glucose and adjust insulin when needed.
    Sources: VMD SPC · VMD
  • Warning
    Use with caution in animals with pre-existing fluid and electrolyte imbalances, since lactulose may exacerbate these conditions, if diarrhoea occurs.
    Sources: VMD SPC · VMD
  • Caution
    Overdosing with lactulose can lead to painful cramping due to gas generation and severe liquid projectile diarrhoea
    Sources: MSD Vet Manual
Latin name
Lactulose
Georgian name
ლაქტულოზა
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
1 of 1 forms
Products
Duphalac
Human medicines in Georgia
Duphalac, LacNovex, Lactuvit, Lopilox, Medulac-WM
Human medicines with this substance in the Georgian register of medicines (Ministry of Health), checked on 18 Oct 2026. They are human medicines, not veterinary products; strengths and forms differ.
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration1

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Duphalac 667 mg/ml, Solution

oral solution, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Hospital rectal retention-enema adjunct for acute hepatic encephalopathy when oral administration is unsafe or inadequate
5.9/10
Weak evidence support
vetman assessment

Duphalac

667 mg/ml, oral solution, human medicine
Assessed clinical scopeDog · Hospital rectal retention-enema adjunct for acute hepatic encephalopathy when oral administration is unsafe or inadequate · Into the rectum
Care settingMonitored hospital care after cleansing enema, with prepared dilution, rectal Foley retention technique, airway/mentation review and serial neurologic and fluid-electrolyte reassessment.
vetman score 5.9/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, human · № რ-045556, რ-046355 · Verified on 15 Oct 2026 Off-label use

A plausible emergency HE adjunct supported by expert consensus, but invasive, preparation-sensitive and untested in controlled target-animal outcome trials.

Regulatory and scientific credibility6.5/10

Exact product identity is strong, but rectal use is absent from its label and from the veterinary comparator label; support is professional consensus rather than a route-specific regulatory dossier.

Clinical efficacy5.5/10

The acidification mechanism and small-animal emergency consensus are plausible, but no controlled dog/cat outcome trial or exact-product rectal study establishes neurologic benefit or superiority.

Safety and tolerability6.0/10

Systemic exposure is minimal, but the exact rectal route lacks target-animal safety data and is used in unstable neurologic patients; mucosal technique, retention, fluid/electrolyte loss and aspiration/mentation context require close oversight.

Clinical practicality5.5/10

The protocol is feasible in hospital but requires cleansing, exact 3:7 preparation, large total volume, rectal Foley placement, 15–20-minute retention and close monitoring; it is not a routine home regimen.

Full-course cost-effectiveness-

A current Georgian exact-pack price, bottle volume and patient-specific duration were not verified, so cost is excluded.

Important safety and use flags

  • Exact human oral product. Georgian/EU human registration and the separate same-strength Laxatract veterinary authorisation do not make Duphalac veterinary-authorised; every assessed dog/cat use is off-label.
  • RECTAL MIXTURE: 20 ml/kg means total 3-parts-Duphalac + 7-parts-water mixture, equal to 6 ml/kg neat product. Giving 20 ml/kg neat Duphalac would be a 3.33-fold product-volume error.
  • Do not use with complete gastrointestinal obstruction, digestive perforation or risk of perforation. Investigate unexplained abdominal pain and distinguish constipation from an obstruction requiring urgent intervention.
  • Titrate to the stated stool endpoint, not to a fixed maximum. Flatulence, distension and cramping can occur early; liquid diarrhoea is excessive treatment, not the therapeutic target.
  • Review hydration and electrolytes before and during intensive or prolonged use. Diarrhoea can worsen dehydration and electrolyte imbalance; reduce/stop the dose and replace deficits when clinically indicated.
  • Duphalac contains lactose, galactose and fructose residues from manufacture. Review diabetes and unusual sugar-intolerance context; HE doses and exposure may be higher than constipation dosing.
  • The current veterinary comparator label reports no known interactions, while the exact human SPC says no interaction studies were performed. Do not infer proven compatibility with every laxative, antacid, antimicrobial or pH-dependent colonic medicine.
  • Hospital technique only: cleansing enema, correct dilution, atraumatic rectal Foley placement and 15–20-minute retention with serial neurologic, airway, hydration and electrolyte reassessment.
  • The authorised veterinary same-strength comparator permits pregnancy and lactation and systemic absorption is minimal, but the exact human product remains off-label; retain an individual benefit-risk review.
  • Do not conflate formulations: exact Duphalac has manufacturing sugar residues and no listed excipient in the cited SPC, whereas Laxatract contains benzyl alcohol. Transfer only the explicitly justified lactulose/concentration evidence.
Assessment sources
  1. Duphalac AEMPS2024
  2. GE Duphalac audit2026
  3. MSD small-animal HE2024
  4. Dog-cat HE review2016
  5. Current liver review2025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Dog Oral lactulose adjunct for diagnosed hepatic encephalopathy or hyperammonaemia, alongside treatment of the cause and precipitating factors
7.0/10
Good
vetman assessment

Duphalac

667 mg/ml, oral solution, human medicine
Assessed clinical scopeDog · Oral lactulose adjunct for diagnosed hepatic encephalopathy or hyperammonaemia, alongside treatment of the cause and precipitating factors · By mouth
Care settingVeterinarian-directed hospital initiation or closely supervised outpatient care, with stool titration and neurologic, hydration and electrolyte reassessment.
vetman score 7.0/10 Good
Evidence confidence: Medium Georgia: Yes, human · № რ-045556, რ-046355 · Verified on 15 Oct 2026 Off-label use

A standard, mechanism-based HE adjunct whose clinical acceptance exceeds its veterinary trial evidence; use only with cause-directed treatment and stool/electrolyte titration.

Regulatory and scientific credibility7.5/10

Exact Duphalac is transparent and human-authorised for HE, and veterinary consensus applies the same locally acting concentration, but the dog/cat indication is off-label and lacks a target-animal regulatory dossier.

Clinical efficacy6.5/10

Lactulose is an established first-line HE adjunct with a clear mechanistic and consensus basis; however, the dog/cat review found no clinical trials, and the 17-dog multimodal cohort informs safety more than efficacy.

Safety and tolerability7.0/10

Local action and mature product warnings are favourable, but HE uses repeated titration and often higher exposure in medically fragile patients, making diarrhoea, dehydration, electrolyte loss and sugar-residue review clinically important.

Clinical practicality7.0/10

PO q8–12h titration is workable at home after stabilisation, but adherence, stool tracking and repeated adjustment are integral rather than optional.

Full-course cost-effectiveness-

A current Georgian exact-pack price, bottle volume and patient-specific duration were not verified, so cost is excluded.

Important safety and use flags

  • Exact human oral product. Georgian/EU human registration and the separate same-strength Laxatract veterinary authorisation do not make Duphalac veterinary-authorised; every assessed dog/cat use is off-label.
  • Use an accurately graduated oral syringe for animal-sized volumes. Do not assume that the human pack measuring cup can measure a small dog or cat dose accurately.
  • Do not use with complete gastrointestinal obstruction, digestive perforation or risk of perforation. Investigate unexplained abdominal pain and distinguish constipation from an obstruction requiring urgent intervention.
  • Titrate to the stated stool endpoint, not to a fixed maximum. Flatulence, distension and cramping can occur early; liquid diarrhoea is excessive treatment, not the therapeutic target.
  • Review hydration and electrolytes before and during intensive or prolonged use. Diarrhoea can worsen dehydration and electrolyte imbalance; reduce/stop the dose and replace deficits when clinically indicated.
  • Duphalac contains lactose, galactose and fructose residues from manufacture. Review diabetes and unusual sugar-intolerance context; HE doses and exposure may be higher than constipation dosing.
  • The current veterinary comparator label reports no known interactions, while the exact human SPC says no interaction studies were performed. Do not infer proven compatibility with every laxative, antacid, antimicrobial or pH-dependent colonic medicine.
  • Treat the liver/shunt cause and precipitating factors; lactulose is an adjunct, not definitive therapy. Do not give orally to a severely obtunded patient without a protected administration plan.
  • The authorised veterinary same-strength comparator permits pregnancy and lactation and systemic absorption is minimal, but the exact human product remains off-label; retain an individual benefit-risk review.
  • Do not conflate formulations: exact Duphalac has manufacturing sugar residues and no listed excipient in the cited SPC, whereas Laxatract contains benzyl alcohol. Transfer only the explicitly justified lactulose/concentration evidence.
Assessment sources
  1. Duphalac AEMPS2024
  2. GE Duphalac audit2026
  3. Laxatract current SPC2026
  4. MSD small-animal HE2024
  5. Dog-cat HE review2016
  6. Canine lactulose safety2024
  7. Current liver review2025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Dog Oral treatment of constipation or clinically indicated facilitated defecation after exclusion of complete obstruction and perforation risk
7.9/10
Good
vetman assessment

Duphalac

667 mg/ml, oral solution, human medicine
Assessed clinical scopeDog · Oral treatment of constipation or clinically indicated facilitated defecation after exclusion of complete obstruction and perforation risk · By mouth
Care settingVeterinarian-directed outpatient treatment with an accurately graduated oral syringe, explicit stool endpoint and reassessment if response is absent after several days.
vetman score 7.9/10 Good
Evidence confidence: Medium Georgia: Yes, human · № რ-045556, რ-046355 · Verified on 15 Oct 2026 Off-label use

A well-supported same-strength osmotic laxative option with favourable safety and flexible dosing; this exact human product remains off-label and must not be used through complete obstruction or perforation risk.

Regulatory and scientific credibility8.0/10

The exact human product has current official identity and Georgian/EU status, while a same-strength oral veterinary lactulose product has current dog/cat authorisation and a public assessment dossier; exact excipients and legal status still differ.

Clinical efficacy8.0/10

A current dog/cat veterinary label and favourable generic assessment support the osmotic-laxative role and dose, but approval relied on an established reference product rather than new comparative outcome trials for exact Duphalac.

Safety and tolerability8.0/10

Less than 2% systemic absorption, mature dog/cat label warnings and permitted pregnancy/lactation support favourable safety; gas and cramps are common, while excess causes diarrhoea, dehydration and electrolyte loss.

Clinical practicality7.5/10

The liquid allows weight-based adjustment, food mixing and dose titration, but usually needs 2–3 daily administrations, may take 2–3 days and requires a suitably graduated oral syringe for small volumes.

Full-course cost-effectiveness-

A current Georgian exact-pack price, bottle volume and patient-specific duration were not verified, so cost is excluded.

Important safety and use flags

  • Exact human oral product. Georgian/EU human registration and the separate same-strength Laxatract veterinary authorisation do not make Duphalac veterinary-authorised; every assessed dog/cat use is off-label.
  • Use an accurately graduated oral syringe for animal-sized volumes. Do not assume that the human pack measuring cup can measure a small dog or cat dose accurately.
  • Do not use with complete gastrointestinal obstruction, digestive perforation or risk of perforation. Investigate unexplained abdominal pain and distinguish constipation from an obstruction requiring urgent intervention.
  • Titrate to the stated stool endpoint, not to a fixed maximum. Flatulence, distension and cramping can occur early; liquid diarrhoea is excessive treatment, not the therapeutic target.
  • Review hydration and electrolytes before and during intensive or prolonged use. Diarrhoea can worsen dehydration and electrolyte imbalance; reduce/stop the dose and replace deficits when clinically indicated.
  • Duphalac contains lactose, galactose and fructose residues from manufacture. Review diabetes and unusual sugar-intolerance context; HE doses and exposure may be higher than constipation dosing.
  • The current veterinary comparator label reports no known interactions, while the exact human SPC says no interaction studies were performed. Do not infer proven compatibility with every laxative, antacid, antimicrobial or pH-dependent colonic medicine.
  • No response after about 2–3 days, recurrent obstipation, vomiting, pain or systemic illness requires diagnostic reassessment rather than automatic dose escalation.
  • The authorised veterinary same-strength comparator permits pregnancy and lactation and systemic absorption is minimal, but the exact human product remains off-label; retain an individual benefit-risk review.
  • Do not conflate formulations: exact Duphalac has manufacturing sugar residues and no listed excipient in the cited SPC, whereas Laxatract contains benzyl alcohol. Transfer only the explicitly justified lactulose/concentration evidence.
Assessment sources
  1. Duphalac AEMPS2024
  2. GE Duphalac audit2026
  3. Laxatract current SPC2026
  4. Laxatract PAR2020
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Hospital rectal retention-enema adjunct for acute hepatic encephalopathy when oral administration is unsafe or inadequate
5.9/10
Weak evidence support
vetman assessment

Duphalac

667 mg/ml, oral solution, human medicine
Assessed clinical scopeCat · Hospital rectal retention-enema adjunct for acute hepatic encephalopathy when oral administration is unsafe or inadequate · Into the rectum
Care settingMonitored hospital care after cleansing enema, with prepared dilution, rectal Foley retention technique, airway/mentation review and serial neurologic and fluid-electrolyte reassessment.
vetman score 5.9/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, human · № რ-045556, რ-046355 · Verified on 15 Oct 2026 Off-label use

A plausible emergency HE adjunct supported by expert consensus, but invasive, preparation-sensitive and untested in controlled target-animal outcome trials.

Regulatory and scientific credibility6.5/10

Exact product identity is strong, but rectal use is absent from its label and from the veterinary comparator label; support is professional consensus rather than a route-specific regulatory dossier.

Clinical efficacy5.5/10

The acidification mechanism and small-animal emergency consensus are plausible, but no controlled dog/cat outcome trial or exact-product rectal study establishes neurologic benefit or superiority.

Safety and tolerability6.0/10

Systemic exposure is minimal, but the exact rectal route lacks target-animal safety data and is used in unstable neurologic patients; mucosal technique, retention, fluid/electrolyte loss and aspiration/mentation context require close oversight.

Clinical practicality5.5/10

The protocol is feasible in hospital but requires cleansing, exact 3:7 preparation, large total volume, rectal Foley placement, 15–20-minute retention and close monitoring; it is not a routine home regimen.

Full-course cost-effectiveness-

A current Georgian exact-pack price, bottle volume and patient-specific duration were not verified, so cost is excluded.

Important safety and use flags

  • Exact human oral product. Georgian/EU human registration and the separate same-strength Laxatract veterinary authorisation do not make Duphalac veterinary-authorised; every assessed dog/cat use is off-label.
  • RECTAL MIXTURE: 20 ml/kg means total 3-parts-Duphalac + 7-parts-water mixture, equal to 6 ml/kg neat product. Giving 20 ml/kg neat Duphalac would be a 3.33-fold product-volume error.
  • Do not use with complete gastrointestinal obstruction, digestive perforation or risk of perforation. Investigate unexplained abdominal pain and distinguish constipation from an obstruction requiring urgent intervention.
  • Titrate to the stated stool endpoint, not to a fixed maximum. Flatulence, distension and cramping can occur early; liquid diarrhoea is excessive treatment, not the therapeutic target.
  • Review hydration and electrolytes before and during intensive or prolonged use. Diarrhoea can worsen dehydration and electrolyte imbalance; reduce/stop the dose and replace deficits when clinically indicated.
  • Duphalac contains lactose, galactose and fructose residues from manufacture. Review diabetes and unusual sugar-intolerance context; HE doses and exposure may be higher than constipation dosing.
  • The current veterinary comparator label reports no known interactions, while the exact human SPC says no interaction studies were performed. Do not infer proven compatibility with every laxative, antacid, antimicrobial or pH-dependent colonic medicine.
  • Hospital technique only: cleansing enema, correct dilution, atraumatic rectal Foley placement and 15–20-minute retention with serial neurologic, airway, hydration and electrolyte reassessment.
  • The authorised veterinary same-strength comparator permits pregnancy and lactation and systemic absorption is minimal, but the exact human product remains off-label; retain an individual benefit-risk review.
  • Do not conflate formulations: exact Duphalac has manufacturing sugar residues and no listed excipient in the cited SPC, whereas Laxatract contains benzyl alcohol. Transfer only the explicitly justified lactulose/concentration evidence.
Assessment sources
  1. Duphalac AEMPS2024
  2. GE Duphalac audit2026
  3. MSD small-animal HE2024
  4. Dog-cat HE review2016
  5. Current liver review2025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Oral lactulose adjunct for diagnosed hepatic encephalopathy or hyperammonaemia, alongside treatment of the cause and precipitating factors
6.8/10
Situational / acceptable
vetman assessment

Duphalac

667 mg/ml, oral solution, human medicine
Assessed clinical scopeCat · Oral lactulose adjunct for diagnosed hepatic encephalopathy or hyperammonaemia, alongside treatment of the cause and precipitating factors · By mouth
Care settingVeterinarian-directed hospital initiation or closely supervised outpatient care, with stool titration and neurologic, hydration and electrolyte reassessment.
vetman score 6.8/10 Situational / acceptable
Evidence confidence: Low Georgia: Yes, human · № რ-045556, რ-046355 · Verified on 15 Oct 2026 Off-label use

A standard, mechanism-based HE adjunct whose clinical acceptance exceeds its veterinary trial evidence; use only with cause-directed treatment and stool/electrolyte titration.

Regulatory and scientific credibility7.5/10

Exact Duphalac is transparent and human-authorised for HE, and veterinary consensus applies the same locally acting concentration, but the dog/cat indication is off-label and lacks a target-animal regulatory dossier.

Clinical efficacy6.0/10

Lactulose is an established small-animal HE adjunct, but no veterinary drug trial was identified and direct feline outcome evidence is particularly sparse; consensus and mechanism therefore carry most of the score.

Safety and tolerability7.0/10

Local action and mature product warnings are favourable, but HE uses repeated titration and often higher exposure in medically fragile patients, making diarrhoea, dehydration, electrolyte loss and sugar-residue review clinically important.

Clinical practicality6.5/10

PO q8–12h is feasible but repeated accurately measured sweet viscous doses and stool titration can be demanding in cats, especially during neurologic illness.

Full-course cost-effectiveness-

A current Georgian exact-pack price, bottle volume and patient-specific duration were not verified, so cost is excluded.

Important safety and use flags

  • Exact human oral product. Georgian/EU human registration and the separate same-strength Laxatract veterinary authorisation do not make Duphalac veterinary-authorised; every assessed dog/cat use is off-label.
  • Use an accurately graduated oral syringe for animal-sized volumes. Do not assume that the human pack measuring cup can measure a small dog or cat dose accurately.
  • Do not use with complete gastrointestinal obstruction, digestive perforation or risk of perforation. Investigate unexplained abdominal pain and distinguish constipation from an obstruction requiring urgent intervention.
  • Titrate to the stated stool endpoint, not to a fixed maximum. Flatulence, distension and cramping can occur early; liquid diarrhoea is excessive treatment, not the therapeutic target.
  • Review hydration and electrolytes before and during intensive or prolonged use. Diarrhoea can worsen dehydration and electrolyte imbalance; reduce/stop the dose and replace deficits when clinically indicated.
  • Duphalac contains lactose, galactose and fructose residues from manufacture. Review diabetes and unusual sugar-intolerance context; HE doses and exposure may be higher than constipation dosing.
  • The current veterinary comparator label reports no known interactions, while the exact human SPC says no interaction studies were performed. Do not infer proven compatibility with every laxative, antacid, antimicrobial or pH-dependent colonic medicine.
  • Treat the liver/shunt cause and precipitating factors; lactulose is an adjunct, not definitive therapy. Do not give orally to a severely obtunded patient without a protected administration plan.
  • The authorised veterinary same-strength comparator permits pregnancy and lactation and systemic absorption is minimal, but the exact human product remains off-label; retain an individual benefit-risk review.
  • Do not conflate formulations: exact Duphalac has manufacturing sugar residues and no listed excipient in the cited SPC, whereas Laxatract contains benzyl alcohol. Transfer only the explicitly justified lactulose/concentration evidence.
Assessment sources
  1. Duphalac AEMPS2024
  2. GE Duphalac audit2026
  3. Laxatract current SPC2026
  4. MSD small-animal HE2024
  5. Dog-cat HE review2016
  6. Current liver review2025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Oral treatment of constipation or clinically indicated facilitated defecation after exclusion of complete obstruction and perforation risk
7.9/10
Good
vetman assessment

Duphalac

667 mg/ml, oral solution, human medicine
Assessed clinical scopeCat · Oral treatment of constipation or clinically indicated facilitated defecation after exclusion of complete obstruction and perforation risk · By mouth
Care settingVeterinarian-directed outpatient treatment with an accurately graduated oral syringe, explicit stool endpoint and reassessment if response is absent after several days.
vetman score 7.9/10 Good
Evidence confidence: Medium Georgia: Yes, human · № რ-045556, რ-046355 · Verified on 15 Oct 2026 Off-label use

A well-supported same-strength osmotic laxative option with favourable safety and flexible dosing; this exact human product remains off-label and must not be used through complete obstruction or perforation risk.

Regulatory and scientific credibility8.0/10

The exact human product has current official identity and Georgian/EU status, while a same-strength oral veterinary lactulose product has current dog/cat authorisation and a public assessment dossier; exact excipients and legal status still differ.

Clinical efficacy8.0/10

A current dog/cat veterinary label and favourable generic assessment support the osmotic-laxative role and dose, but approval relied on an established reference product rather than new comparative outcome trials for exact Duphalac.

Safety and tolerability8.0/10

Less than 2% systemic absorption, mature dog/cat label warnings and permitted pregnancy/lactation support favourable safety; gas and cramps are common, while excess causes diarrhoea, dehydration and electrolyte loss.

Clinical practicality7.5/10

The liquid allows weight-based adjustment, food mixing and dose titration, but usually needs 2–3 daily administrations, may take 2–3 days and requires a suitably graduated oral syringe for small volumes.

Full-course cost-effectiveness-

A current Georgian exact-pack price, bottle volume and patient-specific duration were not verified, so cost is excluded.

Important safety and use flags

  • Exact human oral product. Georgian/EU human registration and the separate same-strength Laxatract veterinary authorisation do not make Duphalac veterinary-authorised; every assessed dog/cat use is off-label.
  • Use an accurately graduated oral syringe for animal-sized volumes. Do not assume that the human pack measuring cup can measure a small dog or cat dose accurately.
  • Do not use with complete gastrointestinal obstruction, digestive perforation or risk of perforation. Investigate unexplained abdominal pain and distinguish constipation from an obstruction requiring urgent intervention.
  • Titrate to the stated stool endpoint, not to a fixed maximum. Flatulence, distension and cramping can occur early; liquid diarrhoea is excessive treatment, not the therapeutic target.
  • Review hydration and electrolytes before and during intensive or prolonged use. Diarrhoea can worsen dehydration and electrolyte imbalance; reduce/stop the dose and replace deficits when clinically indicated.
  • Duphalac contains lactose, galactose and fructose residues from manufacture. Review diabetes and unusual sugar-intolerance context; HE doses and exposure may be higher than constipation dosing.
  • The current veterinary comparator label reports no known interactions, while the exact human SPC says no interaction studies were performed. Do not infer proven compatibility with every laxative, antacid, antimicrobial or pH-dependent colonic medicine.
  • No response after about 2–3 days, recurrent obstipation, vomiting, pain or systemic illness requires diagnostic reassessment rather than automatic dose escalation.
  • The authorised veterinary same-strength comparator permits pregnancy and lactation and systemic absorption is minimal, but the exact human product remains off-label; retain an individual benefit-risk review.
  • Do not conflate formulations: exact Duphalac has manufacturing sugar residues and no listed excipient in the cited SPC, whereas Laxatract contains benzyl alcohol. Transfer only the explicitly justified lactulose/concentration evidence.
Assessment sources
  1. Duphalac AEMPS2024
  2. GE Duphalac audit2026
  3. Laxatract current SPC2026
  4. Laxatract PAR2020
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Lactulose667 mg/ml
Formulation Type
Solution
Administration route
By mouth, Into the rectum
Manufacturer
Abbott Biologicals B.V. / Viatris · Netherlands
Registration
Georgia Yes, human
In force until 22 Sep 2031
Human (Ministry of Health, RAMA)
№ რ-045556, რ-046355
Verified on: 15 Oct 2026
 EU Yes, human
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Veterinary use of this exact human product is off-label. Constipation: 0.6 ml/kg/day PO, preferably divided into 2–3 doses; adjust to effect and allow about 2–3 days. Hepatic encephalopathy: start 0.25–0.5 ml/kg PO q8–12h and titrate to several soft, pudding-like stools, not diarrhoea. Acute HE rectal adjunct: after cleansing enema, use a 3:7 Duphalac:water mixture at 20 ml/kg total mixture, retain 15–20 minutes and reassess neurologic response. The 20 ml/kg is diluted mixture, not neat Duphalac.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 18 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗